Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality Home
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #FDA Approval #Cancer #Novo Nordisk #Quarterly Results

Category: Business

Business News

Eli Lilly Reported a Very Strong Start to 2025, Characterized by Significant Revenue Growth

  • By Athulya B S
  • 1 May 2025
Eli Lilly and Company

Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.

Tagged Eli Lilly and Company, Mounjaro, Q1, Quarterly Results, Zepbound
Regulatory Business Medical Devices News

Roche granted FDA breakthrough device designation for VENTANA TROP2, an AI-driven companion diagnostic for non-small cell lung cancer

  • By Athulya B S
  • 29 April 2025
Roche

The gadget analyzes images using artificial intelligence to achieve a degree of diagnosis accuracy that is not achievable with conventional manual grading techniques.

Tagged Hoffmann-La Roche, VENTANA TROP2
Business Healthcare & Pharmaceuticals News

Amgen Announces $900 Million Worth Expansion of Manufacturing Facility in the US

  • By Ajmal Aseem
  • 26 April 2025
amgen

Amgen has made about $5 billion in direct capital investments in the US since the Tax Cuts and Jobs Act of 2017 was passed.

Tagged Amgen, Business Expansion
Business Healthcare & Pharmaceuticals News

Roche to Invest USD 50 Billion in United States for Pharmaceuticals and Diagnostics Over the Next Five Years

  • By Ajmal Aseem
  • 23 April 2025
Roche

More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.

Tagged Hoffmann-La Roche, Investment, United States
Healthcare & Pharmaceuticals Business Clinical Investigation News

Pfizer Announces Development Discontinuation of Danuglipron an Oral GLP-1 Receptor Agonist

  • By Ajmal Aseem
  • 14 April 2025
pfizer news

Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.

Tagged Danuglipron, GLP-1 Receptor, Pfizer
Business Healthcare & Pharmaceuticals News

mAb Capture Made Cost Effective and Productive With Cytiva’s Protein A Resins

  • By Ajmal Aseem
  • 8 April 2025
cytiva resins

A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of [Read More…]

Tagged Cytiva, Monoclonal Antibodies, Protein A Resins
Clinical Trials Anti-obesity Drugs Business Healthcare & Pharmaceuticals News

Ozempic® Results from STRIDE Shown to Improve Walking Distance and Quality of Life in Adults With Type 2 Diabetes and Peripheral Artery Disease (PAD)

  • By Athulya B S
  • 7 April 2025
novo nordisk

Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.

Tagged Novo Nordisk, Ozempic
Regulatory Approval Business Healthcare & Pharmaceuticals News

U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder

  • By Athulya B S
  • 6 April 2025
amgen

IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.

Tagged FDA Approval, INEBILIZUMAB-CDON, Rare Immune Disorder
Regulatory Business Healthcare & Pharmaceuticals News

Aldeyra Therapeutics Responds to the U.S. FDA’s Denial of Reproxalap’s NDA Application for Treating Signs and Symptoms of Dry Eye Disease

  • By Ajmal Aseem
  • 3 April 2025
US FDA News

FDA stated in the letter that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes”.

Tagged Aldeyra Therapeutics, FDA, Reproxalap
Regulatory Approval Business Healthcare & Pharmaceuticals News

Pfizer’s RSV Lower Respiratory Tract Disease Vaccine ABRYSVO®Approved by European Commission

  • By Ajmal Aseem
  • 1 April 2025
pfizer news

Pfizer Inc (PFI). announced that the European Commission (EC) has amended the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F [Read More…]

Tagged ABRYSVO, Pfizer, RSV

Posts navigation

← Older Posts
→ Newer Posts
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

Novo Ozempic 2 mg MACE Analysis Shows 6% Lower Cardiovascular Risk Versus Switching to Mounjaro at EASD 2026
Research Healthcare & Pharmaceuticals News

Novo Ozempic 2 mg MACE Analysis Shows 6% Lower Cardiovascular Risk Versus Switching to Mounjaro at EASD 2026

29 September 202629 September 2026
Clinical Trials & Data Desk
AbbVie Valkai AI Partnership Deploys Purpose-Built AI Across Targeted Clinical Development Areas
Artificial Intelligence Business Healthcare & Pharmaceuticals News

AbbVie Valkai AI Partnership Deploys Purpose-Built AI Across Targeted Clinical Development Areas

29 September 202629 September 2026
BiotechReality Business Intelligence Desk
Novo HRS-1596 License: Novo Secures Hengrui Pharma’s Oral Once-Weekly GLP-1/GIP Agonist in Deal Worth Up to $2.6 Billion
Business Healthcare & Pharmaceuticals News

Novo HRS-1596 License: Novo Secures Hengrui Pharma’s Oral Once-Weekly GLP-1/GIP Agonist in Deal Worth Up to $2.6 Billion

29 September 202629 September 2026
BiotechReality Business Intelligence Desk
Merck SPR2015 KRAS G12D Inhibitor Deal Strengthens Oncology Pipeline Through $2.13 Billion Agreement
Business Healthcare & Pharmaceuticals News Research

Merck SPR2015 KRAS G12D Inhibitor Deal Strengthens Oncology Pipeline Through $2.13 Billion Agreement

28 September 202628 September 2026
BiotechReality Business Intelligence Desk
AbbVie JUVMO (Tavapadon) Wins FDA Approval as First Selective D1/D5 Receptor Agonist for Parkinson’s Disease
Regulatory Approval Clinical Data Healthcare & Pharmaceuticals News

AbbVie JUVMO (Tavapadon) Wins FDA Approval as First Selective D1/D5 Receptor Agonist for Parkinson’s Disease

28 September 202628 September 2026
Regulatory Intelligence Desk
Merck Ifinatamab Deruxtecan BLA Withdrawn in Previously Treated ES-SCLC
Clinical Data Healthcare & Pharmaceuticals News Regulatory

Merck Ifinatamab Deruxtecan BLA Withdrawn in Previously Treated ES-SCLC

27 September 202627 September 2026
Clinical Trials & Data Desk
Advertisement
BiotechReality JobFinder

  • Component Engineer – Cytiva, Bangalore
    29 September 2026
  • Manufacturing Manager – Novartis, Japan
    28 September 2026
  • Principal Application Specialist FMT APAC – Sartorius, Singapore
    27 September 2026
  • Product Manager – Sanofi, Taipei
    26 September 2026
  • Associate QA Analyst – IQVIA
    14 September 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter